Core Points - Inventiva, a clinical-stage biopharmaceutical company, focuses on developing oral small molecule therapies for metabolic dysfunction-associated steatohepatitis (MASH) and other diseases with significant unmet medical needs [1][7] - The company has reported its half-year liquidity contract with Kepler Cheuvreux, detailing the resources available in its liquidity account as of December 31, 2024 [1][2] Financial Summary - As of December 31, 2024, the liquidity account had cash resources of €349,630.55 and 113,452 shares available [3] - The total number of buy-side executions for the semester was 1,281, with a traded volume of 215,444 shares amounting to €477,452.69 [3][6] - The total number of sell-side executions for the semester was 1,366, with a traded volume of 231,651 shares amounting to €538,913.35 [3][6] Clinical Development - Inventiva's lead product candidate, lanifibranor, is currently in a pivotal Phase III clinical trial (NATiV3) for treating adult patients with MASH [8] - The company has a pipeline that includes odiparcil, which is currently under review for further development after a decision to focus on lanifibranor [9] - Inventiva is also in the process of selecting a candidate for its Hippo signaling pathway program [9] Company Overview - Inventiva has a scientific team of approximately 90 people with expertise in various fields, including biology, medicinal chemistry, and clinical development [10] - The company owns a library of around 240,000 pharmacologically relevant molecules, with about 60% being proprietary [10] - Inventiva is publicly listed on Euronext Paris and Nasdaq, indicating its presence in both European and American markets [11]

Core Insights - Inventiva, a clinical-stage biopharmaceutical company, is focused on developing oral small molecule therapies for metabolic dysfunction-associated steatohepatitis (MASH) and other diseases with significant unmet medical needs [1][5][6] - The results from the Proof-of-Concept trial evaluating lanifibranor in combination with empagliflozin for treating MASH will be presented at the Steatotic Liver Disease Summit 2025 [1][2] Study Details - The LEGEND trial is a multi-center, randomized, placebo-controlled Phase II Proof-of-Concept study assessing the safety and efficacy of lanifibranor (800mg once daily) combined with empagliflozin over a 24-week treatment period in patients with non-cirrhotic MASH and type-2 diabetes (T2D) [2] - The study met its primary efficacy endpoint, showing a significant reduction in HbA1c levels in both the lanifibranor and combination arms compared to placebo [3] - Secondary endpoints also demonstrated therapeutic efficacy, including improvements in liver injury markers, glucose and lipid metabolism, and hepatic steatosis, with no weight gain observed in patients receiving the combination treatment [3] Presentation Details - The abstract titled "The combination of lanifibranor with empagliflozin further enhances metabolic improvement in patients with MASH and T2D" will be presented by Dr. Onno Holleboom on January 25, 2025 [4] Company Overview - Inventiva is advancing its lead product candidate, lanifibranor, which is currently in a pivotal Phase III clinical trial (NATiV3) for treating adult patients with MASH [6] - The company has a pipeline that includes odiparcil for treating adult MPS VI patients, although clinical efforts for odiparcil have been suspended as Inventiva focuses on lanifibranor [7] - Inventiva has a scientific team of approximately 90 people and owns a library of around 240,000 pharmacologically relevant molecules, with about 60% being proprietary [8]

Daix (France), New York City (New York, United States), December 17, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced that Frédéric Cren, CEO and cofounder of Inventiva, has been invit ...

Core Points - Inventiva has successfully secured €21.4 million, completing the first tranche of a multi-tranche equity financing totaling up to €348 million announced on October 14, 2024 [1][2] - The funds from the first tranche will primarily support the Phase III NATiV3 clinical trial for lanifibranor, aimed at treating metabolic dysfunction-associated steatohepatitis (MASH) [1][2] - Mark Pruzanski has been appointed as the new Chairman of the Board, and Srinivas Akkaraju has joined the Board of Directors [1][8] Financing Details - The first tranche of the financing includes a gross amount of €21.4 million, with a net amount of €20.1 million allocated for clinical programs and corporate purposes [1][2] - The company plans to use approximately 85% of the net proceeds for the NATiV3 clinical trial and potential new drug application submission, with the remaining 15% for general corporate purposes [2][3] - The total capital increase from the financing includes €94.1 million from the issuance of new ordinary shares and prefunded warrants [2][3] Financial Position - As of September 30, 2024, Inventiva had cash and cash equivalents of €13.9 million, down from €26.9 million at the end of 2023 [3] - The company estimates an additional cash requirement of €120 million to €130 million to cover obligations until mid-December 2025 [3] - If the second tranche of the financing is completed, it could extend the company's financial visibility beyond 12 months [3] Governance Changes - The Board of Directors has acknowledged the separation of roles between the Chairperson and the CEO, with Mark Pruzanski taking on the Chairperson role [8][9] - The General Meeting approved a remuneration policy for the Chairperson and CEO, along with amendments to the remuneration policies for other executives [8] Shareholder Impact - Following the issuance of the T1 bis Shares and BSAs, the company's share capital will be €949,497.59, divided into 94,949,759 shares [9][12] - The issuance will affect the ownership structure, with existing shareholders experiencing dilution if they do not participate in the financing [12][10]

Core Points - Inventiva, a clinical-stage biopharmaceutical company, focuses on developing oral small molecule therapies for metabolic dysfunction-associated steatohepatitis (MASH/NASH) and other diseases with unmet medical needs [1] - The Combined Shareholders' Meeting held on December 11, 2024, resulted in the adoption of all resolutions except for resolution 59, which was negatively recommended by the Board of Directors [1][2] - The company’s lead product candidate, lanifibranor, is currently in a pivotal phase 3 clinical trial, NATiV3, targeting adult patients with MASH/NASH [6] Shareholder Meeting Results - Total number of shares with voting rights: 86,962,703 [1] - Quorum for the meeting was 79.738% [1] - Resolution 1 received 99.58% approval, while resolution 59 was rejected with 90.24% against [2][5] Voting Results - Ordinary resolutions were largely adopted with high approval rates, such as resolution 1 (99.58%) and resolution 2 (99.58%) [2] - Extraordinary resolutions also saw significant support, with resolution 5 receiving 99.96% approval [3] - The voting results indicate strong shareholder confidence in the company's direction and governance [2][3] Company Overview - Inventiva has a pipeline that includes one clinical candidate and two preclinical programs, with a focus on lanifibranor and a review of odiparcil's development options [6] - The company employs approximately 90 people with expertise in various scientific fields and owns a library of around 240,000 pharmacologically relevant molecules [6] - Inventiva is publicly listed on Euronext Paris and Nasdaq, indicating its commitment to transparency and regulatory compliance [6]

Cash and cash equivalents at €13.9 million, as of September 30, 2024.Revenues of €1.3 million for the first nine months of 2024.On July 18, 2024, Inventiva issued royalty certificates for an amount of €20.1 million.Considering the receipt of €94.1 million in gross proceeds from the closing of the first part of the first tranche of the equity raise announced on October 14, 20242 and the receipt of the $10 million milestone payment under the amended license and collaboration agreement with CTTQ on November 18 ...

The Data Monitoring Committee recommended to continue the clinical trial without modification of the current protocol, based on the pre-planned review of safety data. The recommendation was based on the unblinded review by the DMC of safety data from more than 1000 patients randomized in the main and exploratory cohorts, including over 800 and 170 patients that have been treated for more than 24 and 72 weeks, respectively. This fifth DMC review confirms the good safety profile of lanifibranor. Daix (France) ...

Core Viewpoint - Inventiva announced that the results of the Phase 2 LEGEND trial, evaluating lanifibranor in combination with empagliflozin for patients with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Type-2 Diabetes (T2D), have been accepted for presentation at the 75th Annual AASLD The Liver Meeting® 2024 [1] Group 1: Company Overview - Inventiva is a clinical-stage biopharmaceutical company focused on developing oral small molecule therapies for MASH/NASH and other diseases with significant unmet medical needs [3] - The company is advancing one clinical candidate, lanifibranor, which is currently in a pivotal Phase III clinical trial (NATiV3) for MASH/NASH treatment [3] - Inventiva has a pipeline that includes two preclinical programs and is exploring additional development opportunities [3] Group 2: Product Details - Lanifibranor is an orally-available small molecule that acts as a pan-PPAR agonist, targeting all three PPAR isoforms, which contributes to its favorable tolerability profile observed in clinical trials [2] - The FDA has granted Fast Track and Breakthrough Therapy designations to lanifibranor for MASH/NASH treatment [2] Group 3: Upcoming Presentation - The presentation titled "Combination therapy of lanifibranor with empagliflozin: metabolic improvement in patients with MASH and T2D" will take place on November 18, 2024, from 8:00 AM to 5:00 PM PST [2]

Table of Contents Exhibit 99.1 INVENTIVA S.A. A joint-stock company (société anonyme) with a share capital of 524,771.88 euros Registered office: 50, rue de Dijon, 21121 Daix, France Dijon Trade and Companies Register 537 530 255 INTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 Table of Contents Table of contents 1. Interim Financial Report 3 1.1. General overview of activities 3 1.2. Significant events in the first half of 2024 5 1.3. Recent events and prospects 8 1.4. Risk factors 9 1.5. Ea ...

Daix (France), Long Island City (New York, United States), October 14, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH") and other diseases with significant unmet medical needs, today announces that the Autorité des marchés financiers (the "AMF") has approved a prospectus under no. 24-432, on Octo ...